CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ:LIFE) today announced a new molecular test for the detection of Vesivirus 2117, a potential contaminant of mammalian cell culture based biopharmaceutical manufacturing. The Applied Biosystems ViralSEQTM Vesivirus Detection Kit is a highly sensitive and accurate test that enables the quick isolation and detection of Vesivirus 2117 from cell culture samples. It is expected that biopharmaceutical companies will use the kit to detect this potential contamination early in production, safeguarding the manufacturing processes.
